Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by pro-inflammatory cytokines: potential drug targets

References

• Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther. 2004;6(4):159–168.
   Web of Science ®Google Scholar
• Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32(9):1650–1653.
   PubMed Web of Science ®Google Scholar
• Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–2629.
   PubMed Web of Science ®Google Scholar
• Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. Curr Rheumatol Rev. 2008;4(4):219–234.
   Google Scholar
• Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/ MAPK and JAK/STAT in rheumatoid arthritis and the new antidepression drugs. Expert Opin Ther Targets. 2008;12(2):171–183.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65(2):149–156.
   PubMed Web of Science ®Google Scholar
• Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet. 2008;17(15):2274–2279.
   PubMed Web of Science ®Google Scholar
• Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977–986.
   PubMed Web of Science ®Google Scholar
• Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol. 2009;4:417–434.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity. 2003;36(8):473–479.
   PubMed Web of Science ®Google Scholar
• Glas J, Seiderer J, Nagy M, et al. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn’s disease and early disease onset. PLoS One. 2010;5(4):e10373.
   PubMed Web of Science ®Google Scholar
• Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 2005;18(4):243–249.
   PubMedGoogle Scholar
• Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13(4–5):357–368.
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatol Res Rev. 2009;1:133–150.
   Google Scholar
• Saini M, Pearson C, Seddon B. Regulation of T cell-dendritic cell interactions by IL-7 governs T-cell activation and homeostasis. Blood. 2009;113(23):5793–5800.
   Web of Science ®Google Scholar
• Vogt TK, Link A, Perrin J, Finke D, Luther SA. Novel function for interleukin-7 in dendritic cell development. Blood. 2009;113(17):3961–3968.
   Web of Science ®Google Scholar
• Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):753–759.
   Web of Science ®Google Scholar
• Schmutz S, Bosco N, Chappaz S, et al. Cutting edge: IL-7 regulates the peripheral pool of adult ROR γ+ lymphoid tissue inducer cells. J Immunol. 2009;183(4):2217–2221.
   Web of Science ®Google Scholar
• Malemud CJ. The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflam. 2009;2009:698769.
   Web of Science ®Google Scholar
• Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int. 2001;21(2):69–74.
   Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–1914.
   PubMed Web of Science ®Google Scholar
• Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum. 2007;56(8):2608–2619.
   Google Scholar
• Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol. 2010;71(3):134–145.
   Web of Science ®Google Scholar
• Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs. 2003;4(5):572–577.
   Google Scholar
• Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev. 2007;6:169–175.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum. 2007;56(1):89–100.
   Google Scholar
• Toh ML, Kawashima M, Hot A, Miossec P, Miossec P. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rß2 inhibition. Ann Rheum Dis. 2010;69(8):1562–1567.
   Web of Science ®Google Scholar
• Horvath CM. The Jak-STAT pathway stimulated by interferon alpha or interferon beta. Sci STKE. 2004;2004(260):tr10.
   Google Scholar
• Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Semin Cell Dev Biol. 2008;19(4):311–318.
   PubMed Web of Science ®Google Scholar
• Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNγ signaling – does it mean JAK-STAT? Cytokine Growth Factor Rev. 2008;19(5–6):383–394.
   PubMed Web of Science ®Google Scholar
• Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539–550.
   PubMed Web of Science ®Google Scholar
• Molinero LL, Yang J, Gajewski T, Abraham C, Farrar MA, Alegre ML. CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009;182(11):6736–6743.
   Web of Science ®Google Scholar
• Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther. 2009;4:201–221.
   Web of Science ®Google Scholar
• Jongbloed SL, Benson RA, Nickdel MB, Garside P, McInnes IB, Brewer JM. Plasmacytoid dendritic cells regulate breach of selftolerance in autoimmune arthritis. J Immunol. 2009;182(2):963–968.
   Web of Science ®Google Scholar
• Sozzani S, Vermi W, Prete AD, Fracchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010;31(7):270–277.
   Web of Science ®Google Scholar
• Conigliaro P, Perricone C, Benson RA, et al. The type I IFN system in rheumatoid arthritis. Autoimmunity. 2010;43(3):220–225.
   PubMed Web of Science ®Google Scholar
• Liu H, Leung BP. CD4+CD25+ regulatory T cells in health and disease. Clin Exp Pharmacol Physiol. 2006;33(5–6):519–524.
   Web of Science ®Google Scholar
• Han GM, O’Neill-Andersen NJ, Zurier RB, Lawrence DA. CD4+ CD25 high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253(1–2):92–101.
   Web of Science ®Google Scholar
• Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine. 2009;76(1):10–14.
   Web of Science ®Google Scholar
• Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol. 2010;159(2):109–119.
   PubMed Web of Science ®Google Scholar
• van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol. 2007;2007:89017.
   PubMedGoogle Scholar
• Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 2006;116(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/ STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063–1070.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res. 1999;19(6):563–573.
   PubMed Web of Science ®Google Scholar
• Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 1999;19(1–4):75–120.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in autoimmune rheumatic diseases: relationship with autoantibody profile. Clin Exp Rheumatol. 2002;20(2):213–216.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Rinaldi T, Riccieri V, Valesini G, Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis. 2002;61(2):174–176.
   PubMed Web of Science ®Google Scholar
• Lejuene D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676–33682.
   Web of Science ®Google Scholar
• Travagli J, Letourneur M, Bertoglio J, Pierre J. STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in ketatinocytes. J Biol Chem. 2004;279(34):35183–35192.
   Web of Science ®Google Scholar
• Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 2006;67(1):1–9.
   PubMedGoogle Scholar
• O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487.
   PubMed Web of Science ®Google Scholar
• Tsuji-Takayama K, Suzuki M, Yamamoto M, et al. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Exp Hematol. 2008;36(2):181–192.
   Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1–20.
   PubMed Web of Science ®Google Scholar
• Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene. 2000;19(21):2628–2637.
   PubMed Web of Science ®Google Scholar
• Maritano D, Sugrue ML, Tininini S, et al. The STAT3 isoforms a and ß have unique and special functions. Nat Immunol. 2004;5(4):401–409.
   PubMed Web of Science ®Google Scholar
• El Kasmi KC, Holst J, Coffre M, et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 2006;177(11):7880–7888.
   Web of Science ®Google Scholar
• Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Curr Rheumatol Rev. 2005;1(2):131–142.
   Google Scholar
• Tamai M, Kawakami A, Tanaka F, et al. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-y through JAK/STAT pathway by translational regulation. J Lab Clin Med. 2006;147(4):182–190.
   Web of Science ®Google Scholar
• Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by upregulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. 2010;130(3):418–426.
   Web of Science ®Google Scholar
• Blank VC, Peiia C, Roguin LP STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon- a2b peptide. Exp Cell Res. 2010;316(4):603–614.
   Web of Science ®Google Scholar
• Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005;7(3):100–110.
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti Inflamm Anti Allergy Agents Med Chem. In press 2010.
   Google Scholar
• Hutcheson J, Perlman H. Apoptotic regulators and RA. Curr Rheumatol Rev. 2008;4(4):254–258.
   Google Scholar
• van de Loo FA, Veenbergen S, van den Berg WB. Targeting growth factors in arthritis: a rational for restoring the IGF-1 response in chondrocytes. Curr Rheumatol Rev. 2008;4(4):266–276.
   Google Scholar
• Tallheden T, Dennis JE, Lennon DP, Sjögren-Jansson E, Caplan AI, Lindahl A. Phenotypic plasticity of human articular chondrocytes. J Bone Joint Surg Am. 2003;85-A Suppl 2:93–100.
   Google Scholar
• Neumann A, Dennis JE, Aigner J, et al. Tissue engineering of autologous cartilage grafts in three-dimensional in vitro macroaggregate culture system. Tissue Eng. 2004;10(11–12):1695–1706.
   Google Scholar
• Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468–6472.
   PubMed Web of Science ®Google Scholar
• Huang C, Yang C, Jiang T, Huang K, Cao J, Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29(1):51.
   Google Scholar
• de Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109(4):823–828.
   PubMed Web of Science ®Google Scholar
• Seo IA, Lee HK, Shin YK, et al. Janus kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by suppressing protein translation of gp130. Korean J Physiol Pharmacol. 2009;13(4):131–138.
   Google Scholar
• Wisler BA, Dennis JE, Malemud CJ. New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders. Curr Signal Transduct Ther. In press 2010.
   Google Scholar
• Legendre F, Bogdanowicz P, Boumediene K, Pujol J-P Role of interleukin 6 (IL-6)/IL-6R-induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol. 2005;32(7):1307–1316.
   PubMed Web of Science ®Google Scholar
• Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk between Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007;82(2):237–243.
   PubMed Web of Science ®Google Scholar
• Abram CL, Lowell CA. The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE. 2007;2007(377): re2.
   Google Scholar
• Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol. 2010;17(2):110–116.
   Web of Science ®Google Scholar
• McQueen FM, Dalbeth N. Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders. Med Hypotheses. 2009;73(5):651–654.
   Web of Science ®Google Scholar
• Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5.
   Google Scholar
• Crawford M, Moreland L. Interleukin-6 receptor antagonist as therapy for rheumatoid arthritis. Curr Rheumatol Rep. 2007;9(5):393–394.
   Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Strobl B, Arulampalam V, Is’harc H, et al. A completely foreign receptor can mediate an interferon-γ response. EMBO J. 2001;20(19):5431–5442.
   Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol. 2008;19(4):329–340.
   Web of Science ®Google Scholar
• Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription of binding to NFkB. Genes Dev. 2007;21(11):1396–1408.
   PubMed Web of Science ®Google Scholar
• Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA. 2009;106(23):9373–9378.
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals. 2010;3(5):1446–1455.
   Google Scholar
• Zhang L, Badgwell DB, Bevers JJ 3rd, et al. IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain. Mol Cell Biochem. 2006;288(1–2):179–189.
   Web of Science ®Google Scholar
• Banninger G, Reich NC. STAT2 nuclear trafficking. J Biol Chem. 2004;279(38):39199–39206.
   Web of Science ®Google Scholar
• Darnell JE Jr. STATS and gene regulation. Science. 1997;277(5332):1630–1635.
   PubMed Web of Science ®Google Scholar
• Jaruga B, Hong F, Kim W-H, Gao B. IFN-γ/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol. 2004;287(5):G1044–G1052.
   Web of Science ®Google Scholar
• Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R. Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J Immunol. 2003;171(7):3627–3635.
   Web of Science ®Google Scholar
• Gimeno R, Lee CK, Schindler C, Levy DE. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol. 2005;25(13):5456–5465.
   PubMed Web of Science ®Google Scholar
• Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17 and Th1 cells. Proc Natl Acad Sci USA. 2009;106(32):13463–13468.
   PubMed Web of Science ®Google Scholar
• Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 is necessary and sufficient for IL-4’s role in Th2 differentiation and cell expansion. J Immunol. 2001;166(12):7276–7281.
   PubMed Web of Science ®Google Scholar
• Kaplan MH. STAT4. A critical regulator of inflammation in vivo. Immunol Res. 2005;31(3):231–242.
   Web of Science ®Google Scholar
• Akira S. IL-6-regulated transcription factors. Int J Biochem Cell Biol. 1997;29(12):1401–1418.
   Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297–314.
   PubMed Web of Science ®Google Scholar
• Hintzen C, Haan C, Tuckermann JP, Heinrich PC, Hermanns HM. Oncostatin-M-induced and constitutive activation of the JAK2/ STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. J Immunol. 2008;181(10):7341–7349.
   Web of Science ®Google Scholar
• Cvijic H, Bauer K, Löffler D, et al. Co-activator SRC-1 is dispensable for transcriptional control by STAT3. Biochem J. 2009;420(1):123–132.
   Google Scholar
• Andreas K, Häupl T, Lübke C, et al. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
   PubMed Web of Science ®Google Scholar
• Gu L, Chiang KY, Zhu N, Findley HW, Zhou M. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines. Exp Hematol. 2007;35(6):957–966.
   Web of Science ®Google Scholar
• Legendre F, Dudhia J, Pujol J-P, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem. 2003;278(5):2903–2912.
   PubMed Web of Science ®Google Scholar
• Brocke-Heidrich K, Ge B, Cvijic H, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene. 2006;25(55):7297–7304.
   Web of Science ®Google Scholar
• Snyder M, Huang XY, Zhang JJ. Identification of novel Stat3 target genes for control of growth and differentiation. J Biol Chem. 2008;283(7):3791–3798.
   PubMed Web of Science ®Google Scholar
• Krona A, Aman P, Orndal C, Josefsson A. Oncostatin M-induced genes in human astrocytoma. Int J Oncol. 2007;31(6):1457–1463.
   Web of Science ®Google Scholar
• Bourillot PY, Aksoy I, Schreiber V et al. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells. 2009;27(8):1760–1771.
   Web of Science ®Google Scholar
• Seki Y, Yang J, Okamoto M, et al. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naïve CD4 T cell survival in peripheral lymphoid organs. J Immunol. 2007;178(1):262–270.
   Web of Science ®Google Scholar
• Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest. 2004;33(2):109–142.
   PubMed Web of Science ®Google Scholar
• Khaled AR, Li WQ, Huang J. Bax deficiency partially corrects interleukin-7 receptor α deficiency. Immunity. 2002;17(5):561–573.
   Web of Science ®Google Scholar
• Khaled AR, Durum SK. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev. 2003;193:48–57.
   PubMed Web of Science ®Google Scholar
• Kim H-R, Hwang K-A, Park S-H, Kang I. IL-7 and IL-15: biology and roles in T cell immunity in health and disease. Crit Rev Immunol. 2008;28(4):325–339.
   Web of Science ®Google Scholar
• Sawa S-I, Kamimura D, Jin G-H, et al. Autoimmune arthritis associated with mutated interleukin (IL-6) receptor gp130 is driven by STAT3/ IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med. 2006;203(6):1459–1470.
   Web of Science ®Google Scholar
• Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-induced JakSTAT signaling by glucocorticoids. Proc Natl Acad Sci U S A. 2000;97(17):9573–9578.
   PubMed Web of Science ®Google Scholar
• Jahn T, Sindhu S, Gooch S, et al. Direct interaction between Kit and the interleukin-7 receptor. Blood. 2007;110(6):1840–1847.
   Web of Science ®Google Scholar
• Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42(5):963–970.
   PubMedGoogle Scholar
• Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7(1):29–37.
   PubMed Web of Science ®Google Scholar
• Koenders MI, Lubberts E, van de Loo FAJ, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol. 2006;176(10):6262–6269.
   Web of Science ®Google Scholar
• Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008;226:132–146.
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity. 2008;28(1):29–39.
   PubMed Web of Science ®Google Scholar
• Takatori H, Kanno Y, Chen Z, O’Shea JJ. New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod Rheumatol. 2008;18(6):533–541.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517.
   PubMed Web of Science ®Google Scholar
• Nishihara M, Ogura H, Ueda N, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of T in the steady state. Int Immunol. 2007;19(6):695–702.
   Web of Science ®Google Scholar
• de Breegaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205(7):1543–1550.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Rudra D, Treuting P, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009;326(5955):986–991.
   Web of Science ®Google Scholar
• Lee Y-H, Benary M, Baumgrass R, Herzel H. Prediction of regulatory transcription factors in T helper cell differentiation and maintenance. Genome Inform. 2010;22:84–94.
   Google Scholar
• Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kB and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6(2):R120–R128.
   PubMed Web of Science ®Google Scholar
• Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis M-A, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182(5):3112–3120.
   PubMed Web of Science ®Google Scholar
• Lexberg MH, Taubner A, Förster A, et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol. 2008;38(10):2654–2664.
   PubMed Web of Science ®Google Scholar
• Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8(1):40–52.
   PubMedGoogle Scholar
• Partham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R²1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708.
   Web of Science ®Google Scholar
• Wada Y, Lu R, Zhou D, et al. Selective abrogation of the Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007;109(3):1156–1164.
   PubMed Web of Science ®Google Scholar
• Kim H-R, Cho M-L, Kim K-W, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase, NFγB and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford). 2007;46(1):57–64.
   Web of Science ®Google Scholar
• Liu FL, Chen CH, Chu SJ, et al. Interleukin (IL)-23p19 expression induced by IL-1² in human fibroblast-synoviocytes with rheumatoid arthritis via active nuclear factor γβ and AP-1 dependent pathway. Rheumatology (Oxford). 2007;46(8):1266–1273.
   Web of Science ®Google Scholar
• Kusaba H, Ghosh P, Derin R, et al. Interleukin-12-induced interferon-γ production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J Biol Chem. 2005;280(2):1037–1043.
   Web of Science ®Google Scholar
• Xu H, Zhang Y, Hua Y, Chen T, Wang H, Wu W. IL-12 p35 silenced dendritic cells modulate immune responses by blocking IL-12 signaling through JAK-STAT pathways in T lymphocytes. Biochem Biophys Res Commun. 2007;353(3):812–816.
   Web of Science ®Google Scholar
• Lund R, Chen Z, Scheinin J, Lahesmaa R. Early target genes of IL-12 and STAT4 signaling in Th cells. J Immunol. 2004;172(11):6775–6782.
   Web of Science ®Google Scholar
• Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3α in patients with rheumatoid arthritis. Rheumatol Int. 2007;28(2):137–143.
   Web of Science ®Google Scholar
• Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity. 2010;43(3):196–203.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: insights into the pathogenesis of inflammatory arthritis. Immunol Rev. 2010;233(1):79–96.
   Google Scholar
• Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007;89(6–7):729–734.
   Web of Science ®Google Scholar
• Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC. Activation of STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus. 2007;16(2):101–109.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):339–347.
   PubMed Web of Science ®Google Scholar
• Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69(6):945–948.
   Web of Science ®Google Scholar
• Christova R, Jones T, Wu PJ, et al. P-STAT1 mediates higher-order chromatin remodeling of the human MHC in response to IFNγ. J Cell Sci. 2007;120(Pt 18):3262–3270.
   Web of Science ®Google Scholar
• Vogl C, Flatt T, Fuhrmann B, et al. Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes. BMC Genomics. 2010;11:199.
   PubMed Web of Science ®Google Scholar
• Watling D, Carmo CR, Kerr IM, Costo-Pereira AP. Multiple kinases in the interferon-γ response. Proc Natl Acad Sci U SA. 2008;105(16):6051–6056.
   Web of Science ®Google Scholar
• Joshi S, Kaur S, Kroczynska B, Platanias LC. Mechanisms of mRNA translation of the interferon stimulated genes. Cytokine. 2010;52 (1–2):123–127.
   Google Scholar
• Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A, Zoon KC. IRF9 is a key factor for eliciting the anti-proliferative activity of IFN-α. J Immunother. 2009;32(8):803–816.
   Web of Science ®Google Scholar
• Kaur S, Uddin S, Platanias LC. The PI3’ kinase pathway in interferon signaling. J Interferon Cytokine Res. 2005;25(12):780–787.
   Web of Science ®Google Scholar
• Kaur S, Sassano A, Dolniak B, et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A. 2008;105(12):4808–4813.
   PubMed Web of Science ®Google Scholar
• Kaur S, Katsoulidis E, Platanias LC. Akt and mRNA translation by interferons. Cell Cycle. 2008;7(14):2112–2116.
   PubMed Web of Science ®Google Scholar
• Kaur S, Sassano A, Joseph AM, et al. Dual regulatory roles of phosphatidylinositol-3-kinase in IFN-signaling. J Immunol. 2008;181(10):7316–7323.
   Web of Science ®Google Scholar
• Andreas K, Lübke C, Häupl T, et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008;10(1):R9.
   PubMed Web of Science ®Google Scholar
• Waldburger J-M, Firestein GS. . Signaling pathways in rheumatoid arthritis. In: Tak P-P, editor. Progress in Inflammation Research. Basel, Switzerland: Birkhäuser; 2009:155–180.
   Google Scholar
• Lee HM, Mima T, Sugino H, et al. Interactions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(1):R1.
   Web of Science ®Google Scholar
• Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8(5):379–383.
   PubMed Web of Science ®Google Scholar
• Sweeney SE, Kimbler TB, Firestein GS. Synoviocyte innate immune responses. II. Pivotal role of IFN regulatory factor 3. J Immunol. 2010;184(12):7162–7168.
   Web of Science ®Google Scholar
• Österlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J Immunol. 2007;179(6):3434–3442.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene. 2000;19(21):2557–2565.
   PubMed Web of Science ®Google Scholar
• Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of anti-inflammatory effects of IL-10 in human macrophages. J Immunol. 2004;172(1):567–576.
   Web of Science ®Google Scholar
• Wang M, Liang P. Interleukin-24 and its receptors. Immunology. 2005;114(2):166–170.
   PubMed Web of Science ®Google Scholar
• Trivella DB, Ferreira-Junior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci. 2010;67(17):2909–2935.
   Web of Science ®Google Scholar
• Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol. 2010;32(1):17–31.
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003;21:713–758.
   PubMed Web of Science ®Google Scholar
• Mowen KA, Glimcher LM. Signaling pathways in Th2 development. Immunol Rev. 2004;202:203–222.
   PubMed Web of Science ®Google Scholar
• Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and IL4 locus susceptibility. Annu Rev Immunol. 2006;24:607–656.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORy t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Kimura MY. Memory Th1/Th2 cell generation controlled by Schnurri-2. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York, NY: Springer Science; 2010:1–9.
   Google Scholar
• Hermann J, Gruber S, Neufeld JB, et al. IL10R1 loss-of-fonction alleles in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27(4):603–608.
   Web of Science ®Google Scholar
• Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999;274(23):16513–16521.
   PubMed Web of Science ®Google Scholar
• Ahmed ST, Ivashkiv LB. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol. 2000;165(9):5227–5237.
   Web of Science ®Google Scholar
• Herrero C, Hu X, Li WP, et al. Reprogramming of IL-10 activity and signaling by IFN-γ. J Immunol. 2003;171(10):5034–5041.
   PubMed Web of Science ®Google Scholar
• Ji JD, Tassiulas I, Park-Min KH, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med. 2003;197(11):1573–1583.
   PubMed Web of Science ®Google Scholar
• van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc Y receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol. 2003;30(4):648–651.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol. 2008;180(9):6325–6333.
   Web of Science ®Google Scholar
• Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R93.
   Google Scholar
• Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connection maps. Science. 2003;300(5625):1527–1528.
   PubMed Web of Science ®Google Scholar
• Ratthé C, Pelletier M, Chiasson S, Girard D. Molecular mechanisms involved in interleukin-4-induced human neutrophils: expression and regulation of suppressor of cytokine signaling. J Leukoc Biol. 2007;81(5):1287–1296.
   Web of Science ®Google Scholar
• Wang IM, Lin H, Goldman SJ, Kobayashi M. STAT-1 is activated by IL-4 and IL-13 in multiple cell types. Mol Immunol. 2004;41(9):873–884.
   PubMed Web of Science ®Google Scholar
• Morita Y, Yamamura M, Kawashima M, et al. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int. 2001;20(2):49–54.
   PubMed Web of Science ®Google Scholar
• Woods JM, Katschke KJ, Volin MV et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol. 2001;166(2):1214–1222.
   PubMed Web of Science ®Google Scholar
• Nabbe KC, van Lent PL, Holthuysen AE, et al. Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation. Arthritis Res Ther. 2005;7(2):R392–R401.
   PubMed Web of Science ®Google Scholar
• Relic B, Guicheux J, Mezin F, et al. IL-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. J Immunol. 2001 ;166(4):2775–2782.
   Web of Science ®Google Scholar
• Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F. High levels of interleukin-13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. J Rheumatol. 2002;29(3):454–461.
   PubMed Web of Science ®Google Scholar
• Woo KM, Kim HM, Ko JS. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med. 2002;34(5):340–346.
   Web of Science ®Google Scholar
• Rumore-Maton B, Elf J, Belkin N, et al. M-CSF and GM-CSF regulation of STAT5 activation and DNA binding in myeloid cell differentiation is disrupted in nonobese diabetic mice. Clin Dev Immunol. 2008;2008:769795.
   Google Scholar
• Haas CS, Amin MA, Allen BB, et al. Inhibition of angiogenesis by interleukin-4 therapy in rat adjuvant-induced arthritis. Arthritis Rheum. 2006;54(8):2402–2414.
   PubMedGoogle Scholar
• Haas CS, Amin MA, Ruth JH, et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum. 2007;56(8):2535–2548.
   PubMedGoogle Scholar
• Ruth JH, Haas CS, Park CC, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent on the MAPK pathway. Arthritis Rheum. 2006;54(3):765–778.
   Google Scholar
• Thornton AM. Signal transduction in CD4+ CD25+ regulatory T cells: CD25 and IL-2. Front Biosci. 2006;11:921–927.
   Google Scholar
• Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19(21):2566–2576.
   Web of Science ®Google Scholar
• Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/ STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006;1079:198–204.
   PubMed Web of Science ®Google Scholar
• Taylor DK, Walsh PT, LaRossa DF, et al. Constitutive activation of STAT5 supersedes the requirement for cytokine and TCR engagement of CD4+ cells in steady-state homeostasis. J Immunol. 2006;177(4):2216–2223.
   Web of Science ®Google Scholar
• Franceschini D, Paroli M, Francavilla V et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119(3):551–564.
   Web of Science ®Google Scholar
• Streitholt S, Maurer B, Peters MA, Pap T, Gay S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther. 2008;10(5):219.
   Web of Science ®Google Scholar
• Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol. 2009;5(5):266–272.
   PubMed Web of Science ®Google Scholar
• Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun. 2010;34(3): J207–J219.
   PubMed Web of Science ®Google Scholar
• Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18(11):545–551.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Park HY, Jeong SJ, et al. STAT4 expression in human T cells is regulated by DNA methylation but not by promoter polymorphism. J Immunol. 2005;175(11):7143–7150.
   PubMed Web of Science ®Google Scholar
• Kim EG, Shin HJ, Lee CG, et al. DNA methylation and not allelic variation regulates STAT6 expression in human T cells. Clin Exp Med. 2010;10(3):143–152.
   Web of Science ®Google Scholar
• Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX. JAK signaling globally counteracts heterochromatin gene silencing. Nat Genet. 2006;38(9):1071–1076.
   Web of Science ®Google Scholar
• Nile CJ, Read AC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 2008;58(9):2686–2693.
   PubMedGoogle Scholar
• van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):549–553.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, doubleblind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929–939.
   PubMed Web of Science ®Google Scholar
• Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/ IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs. 2008;9(5):515–522.
   PubMedGoogle Scholar
• Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9(8):1107–1113.
   PubMed Web of Science ®Google Scholar
• Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182:97–110.
   PubMed Web of Science ®Google Scholar
• Hartgring SAY, van Roon JAG, Wijk MWV et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7- induced immune activation in rheumatoid arthritis. Arthritis Rheum. 2009;60(9):2595–2605.
   Google Scholar
• Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis. 2010 Jun 15. [Epub ahead of print] PMID: 20551157.
   Web of Science ®Google Scholar
• O’Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004;3(7):555–564.
   PubMed Web of Science ®Google Scholar
• Feely MG. New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatol Res Rev. 2010;2:35–43.
   PubMedGoogle Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895–1905.
   PubMed Web of Science ®Google Scholar
• Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69(2):413–416.
   Web of Science ®Google Scholar
• Kim BH, Oh SR, Yin CH, et al. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol. 2010;148(1):132–143.
   Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/JAK2 inhibitor ICNB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–3117.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307.
   PubMed Web of Science ®Google Scholar
• Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res. 2008;466(9):2168–2175.
   Web of Science ®Google Scholar
• Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232–5240.
   PubMed Web of Science ®Google Scholar
• Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311–320.
   PubMed Web of Science ®Google Scholar
• Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321–330.
   PubMed Web of Science ®Google Scholar
• Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 2005;24(20):3236–3245.
   Web of Science ®Google Scholar
• Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102(11):1592–1599.
   PubMed Web of Science ®Google Scholar
• Zhang L, Alizadeh D, van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 2009;57(13):1458–1467.
   PubMed Web of Science ®Google Scholar
• Spagnoli A, Torello M, Nagalla SR, et al. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J Biol Chem. 2002;277(21):18860–18867.
   Web of Science ®Google Scholar
• Shipley JM, Waxman DJ. Down-regulation of STAT 5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) α and PPARγ. Mol Pharmacol. 2003;64(2):355–364.
   Web of Science ®Google Scholar
• Böhm C, Hayer S, Kilian A, et al. The α-isoform of p38 kinase MAPK specifically regulates arthritic bone loss. J Immunol. 2009;183(9):5938–5947.
   Web of Science ®Google Scholar
• Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009;60(2):317–320.
   PubMed Web of Science ®Google Scholar
• Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69 Suppl 1:i77–i82.
   Google Scholar